OneMedNet Corp - Warrant (ONMDW)

As a risk manager looking at ONMDW, the equity and warrants present an acute restructuring risk. With cash reserves dwindling to around $0.4 million against $4.9 million in total liabilities and management formally flagging going concern warnings, the capital structure is heavily stressed. The warrants are down over 50% year-to-date, trading at fractional cents, reflecting extreme distress and minimal recovery expectations if liquidity dries up entirely before a turnaround or dilutive rescue financing materializes.

On our desk, market sentiment for ONMDW is deeply cautious. While 10 hedge funds and institutions held a modest $179K in warrants during Q2 2026, the overall position turnover points to fading interest. The underlying stock is under immense pressure from Nasdaq after receiving a minimum bid-price notification, giving them until October 12, 2026, to regain compliance, potentially forcing management into a severe reverse stock split that would further crush warrant holders.

From a clinical data engineering perspective, OneMedNet's underlying product value—curating regulatory-grade medical imaging Real World Data (RWD) via iRWD—has functional merit for life science partners seeking precise case selection protocols. However, the operational pivot away from legacy BEAM subscriptions toward data delivery has not yet translated into gross profitability, as evidenced by quarterly gross losses of $0.6 million and an operating loss of $2.3 million.

Watching the 50-day and 200-day moving averages on ONMD, the equity action bleeds directly into the derivatives. With the warrant trading around $0.03 to $0.04 and down roughly 53% since the start of the year, implied volatility is pricing in binary outcomes. Any desperate equity issuance or debt restructuring move will likely obliterate the remaining delta on these out-of-the-money warrants.

On our trading desk, liquidity in ONMDW is practically nonexistent for large block executions. The tiny market cap of under $1 million for the warrants means spreads are wide and slippage is severe. Unless an unexpected catalyst emerges to push the core stock back above $1.00 sustainably, these warrants are destined for complete expiration with zero intrinsic value.